title: Does erythropoietin administration affect progression of atherosclerosis in Watanabe heritable hyperlipaemic rabbits?
authors.forename: M
authors.initials: M
authors.lastname: Buemi
authors.forename: A
authors.initials: A
authors.lastname: Allegra
authors.forename: F
authors.initials: F
authors.lastname: Corica
authors.forename: G
authors.initials: G
authors.lastname: Calapai
authors.forename: G
authors.initials: G
authors.lastname: Cavallaro
authors.forename: C
authors.initials: C
authors.lastname: Aloisi
authors.forename: G
authors.initials: G
authors.lastname: Pettinato
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.forename: N
authors.initials: N
authors.lastname: Frisina
mesh_terms: D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001018:Aortic Diseases / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D002788:Cholesterol Esters / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D004921:Erythropoietin / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000235:genetics; D008055:Lipids / Q000097:blood; D008297:Male; D011817:Rabbits; D011994:Recombinant Proteins
chemical_list: D002788:Cholesterol Esters; D008055:Lipids; D011994:Recombinant Proteins; D004921:Erythropoietin